Letter to Financial Times

Sir, Clive Cookson is right to draw attention to environmental groups targeting nanotechnology ("Call for nanotechnology regulation to head off fears over 'killer dust'", January 15). I fear that all too few people in the nanotechnology (and insurance) industries are fully aware of the dangers.

It may be straightforward to dismiss the notion that self-replicating nano-machines will run amok and turn everything into a "killer dust". Somewhat harder tasks lie ahead. For instance, it is likely that the industry will have to deal with the claim, made by certain environmentalists, that nano-size carbon is highly toxic, and has the ability to enter a living cell without triggering the cell's defences. Headline-grabbing claims that a carbon nano-tube represents the "asbestos of the future" are often made consistent with a suggestive reading of the scientific literature.

The nanotechnology industry must ensure that it is fully educated about possible environmental pitfalls. The financial implications of remaining ignorant are obvious to all.

Understanding Nanotoxicity: Why Size Matters

At the heart of the environmentalists’ warnings lies a genuine scientific puzzle: why should a lump of carbon in pencil lead be safe, while a nanotube—essentially the same element arranged in a tube—might be dangerous? The answer is a matter of scale. When materials are reduced to dimensions between 1 and 100 nanometres, they can exhibit novel physical, chemical, and biological properties. The high surface-area-to-volume ratio means a far greater proportion of atoms are on the surface, making the material more reactive. This can lead to the generation of reactive oxygen species, which cause oxidative stress in living tissues—a known pathway to inflammation, DNA damage, and even cancer.

Carbon nanotubes, in particular, raise alarm because of their structural resemblance to asbestos fibres. Asbestos is a naturally occurring mineral fibre that, when inhaled, can become lodged in the lungs and cause mesothelioma decades later. Studies have demonstrated that certain long, rigid carbon nanotubes can induce similar pre-cancerous lesions in the mesothelial lining of mice. The key parameters appear to be fibre length, diameter, and biopersistence—properties that must be assessed for any engineered nanomaterial. However, not all nanoparticles are alike; spherical gold nanoparticles, for instance, can be ingested with minimal effect, while cadmium-based quantum dots are highly toxic. The ability of nanoparticles to cross cell membranes, the blood–brain barrier, and even the placenta is both a promise for drug delivery and a peril for unintended exposure.

The claim that nano-sized carbon can enter a cell without triggering its defences is supported by research showing that certain nanoparticles evade the normal phagocytic response. Once inside, they can interfere with cellular machinery, cause mitochondrial damage, or trigger unregulated signalling. The scientific community is only beginning to unravel these mechanisms, but the message is clear: we cannot assume that bulk-material safety data is sufficient for the nanoscale. A robust toxicological framework is urgently needed.

Learning from Past Industrial Disasters

The comparison to asbestos is not mere scaremongering; it is a salutary lesson from industrial history. The devastating health effects of asbestos were known to some manufacturers as early as the 1930s, yet widespread regulation did not arrive until the late twentieth century. In the interim, millions were exposed, and the global cost of asbestos-related disease and litigation runs into hundreds of billions of pounds. A similar pattern emerged with lead in paint, the pesticide DDT, and chlorofluorocarbons (CFCs), where early warnings were ignored until the evidence became incontrovertible. The precautionary principle, now embedded in European Union law, holds that where there are threats of serious or irreversible damage, lack of full scientific certainty should not be used as a reason for postponing cost-effective measures to prevent harm.

For nanotechnology, the stakes are uniquely high because of its cross-cutting applications—from electronics and cosmetics to food packaging and medicine. A single poorly understood nanomaterial could become widely disseminated before its risks are identified, making recall impossible. The insurance industry, often a bellwether for emerging risks, is already grappling with the question of whether standard liability policies cover nanoparticle exposure. Some insurers are beginning to exclude nanotechnology-related claims, citing the unknown long-tail risk. If insurers pull back, the financial burden on companies—and ultimately society—could be immense.

Historically, industries have often lobbied against regulation, arguing it stifles innovation. But regulation, when done right, can actually foster innovation by creating a level playing field and earning public trust. The nanotechnology sector has a chance to get ahead of the curve, learning from the mistakes of its predecessors. This means embracing transparency, funding independent research, and engaging with regulators proactively rather than defensively.

The Patchwork of Nanotechnology Regulation

At present, the regulatory landscape for nanomaterials is fragmented and often inadequate. In the European Union, the REACH regulation (Registration, Evaluation, Authorisation and Restriction of Chemicals) was amended to include explicit provisions for nanoforms, but implementation has been slow. Member states struggle with the sheer complexity of characterising and registering nanomaterials, and many substances remain on the market without comprehensive safety dossiers. The United States follows a largely risk-based approach under the Toxic Substances Control Act (TSCA), but until recent amendments, it lacked the authority to require safety testing for new chemicals. Other jurisdictions, like Japan and South Korea, have developed their own frameworks, but harmonisation is minimal.

International bodies such as the Organisation for Economic Co-operation and Development (OECD) have established working groups to develop test methods and guidance, but progress is incremental. The lack of standardised definitions—what precisely constitutes a nanomaterial—remains a fundamental hurdle. Without a clear definition, regulatory thresholds and labelling requirements become arbitrary. Voluntary reporting schemes, such as the UK’s voluntary reporting scheme for engineered nanomaterials, have seen low participation, undermining their usefulness for risk assessment. The following approaches illustrate the current diversity:

• Precautionary approaches: as in the EU, shifting the burden of proof to industry;
• Risk-based frameworks: as in the US, requiring demonstrated risk before action;
• Product-specific regulations: sectoral rules for cosmetics, food, or pesticides that may capture some nanomaterials;
• Voluntary reporting: seen in several countries, but often insufficient for comprehensive oversight.

A truly effective regulatory system would require mandatory pre-market safety testing, based on validated in vitro and in vivo methods tailored to nanoscale properties. It would also need to cover the entire lifecycle of a product, from manufacture to disposal, considering environmental accumulation. Crucially, it must be flexible enough to adapt as the science evolves. The financial services industry has a role to play: lenders and investors should demand evidence of regulatory compliance and robust risk management before providing capital. Without such market pressure, change will remain sluggish.

What the Nanotechnology Industry Must Do

The letter’s admonition that “the nanotechnology industry must ensure that it is fully educated about possible environmental pitfalls” is both a call to arms and a statement of self-interest. Education begins with investing in toxicology and environmental fate studies, not merely as a compliance exercise but as a core part of product development. Companies should adopt “safe-by-design” principles, where hazard reduction is engineered into the nanomaterial from the outset—for example, by using coatings that prevent dissolution or by designing particles that aggregate harmlessly in the environment.

Transparency is equally critical. The public has a right to know which products contain engineered nanomaterials, and workers in manufacturing facilities deserve full information about exposure risks. Industry associations, such as the Nanotechnology Industries Association, have published best-practice guides, but uptake remains voluntary and often limited to larger firms. Smaller enterprises, which form the backbone of many nanotech innovations, frequently lack the resources or awareness to engage. Mandatory disclosure requirements, combined with public–private funding for safety research, could help level the playing field.

Furthermore, the industry must abandon the dismissive stance it has sometimes adopted towards critics. While the “killer dust” narrative is hyperbolic, legitimate scientific concerns deserve a considered response. By engaging in open dialogue with environmental groups, regulators, and the media, the industry can build the trust that is essential for long-term market acceptance. The financial implications of remaining ignorant are not just about lawsuits; they include lost markets, boycotted products, and the high cost of retroactive regulation.

Navigating Public Perception and Media Narratives

Public perception of nanotechnology has been shaped largely by media coverage, which often vacillates between utopian promises and dystopian warnings. The “grey goo” scenario popularised by science fiction, while scientifically implausible, lingers in the public imagination and colours every new report. Environmental campaigning groups, sensing this vulnerability, have been quick to frame nanoparticles as a new invisible threat. Their effectiveness lies not in the most extreme claims but in the more subtle and evidence-based assertions, such as the asbestos analogy, which are harder to refute.

Responsible journalism has a vital role to play in contextualising risks. Rather than simply reporting that “carbon nanotubes are the new asbestos,” reporters should explain the specific conditions under which harm might occur, the dosage required, and the steps being taken to manage the risk. Editors should resist the temptation to sensationalise; scientists and industry spokespersons must learn to communicate uncertainty without either over-reassurance or alarmism. The Financial Times itself, through balanced articles like Mr Cookson’s, demonstrates how nuanced coverage can inform rather than inflame.

Ultimately, the public will judge nanotechnology not by its promise but by its safety record. If the industry ignores the early warnings and a real harm emerges, the backlash could be swift and severe, potentially derailing a field that holds tremendous potential in medicine, energy, and materials science. The window of opportunity to get things right is still open, but it is narrowing. As the original letter argued, the financial implications of inaction are glaring. The time for education, precaution, and constructive engagement is now.